Personalized Medicine and Medicinal Chemistry: Towards a Legal Frame-work in the European Union

被引:2
|
作者
Duardo-Sanchez, Aliuska [1 ]
De Miguel Beriain, Inigo [1 ,2 ]
机构
[1] Univ Basque Country UPV EHU, Chair Law & Human Genome Res Grp, Dept Publ Law, Leioa 48940, Biscay, Spain
[2] Basque Fdn Sci, IKERBASQUE, Bilbao 48011, Biscay, Spain
基金
欧盟地平线“2020”;
关键词
Personalized medicine; Medicinal chemistry; Legal issues; Genomics; Data protection; Clinical trials;
D O I
10.2174/1568026619666181120144213
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In the last few years, the fields of Medicinal Chemistry and especially the ones related to the so-called Personalized Medicine, have received a great attention. Significant investment and remarkable researches surround the matter; however, not all those promising advances are reaching patients as quickly as they should. The absence of an adequate regulatory framework could be of no help. The complete and/or massive sequencing of individual genomes faces many ethical-legal challenges. Some of them are access to Personalized Medicine; the treatment of a large volume of sensitive information and the use of tools produced by "big data" systems in clinical care or in predictive models. In addition, the legal protection of personal data related to health, the exercise of autonomy by patients, closely related to the regulation regarding clinical trials, are seriously involved. Our purpose of this work is to review the regulations of the European Union, in an attempt to contribute to a better understanding of the legal framework for the implementation and development of health systems based on Personalized Medicine.
引用
收藏
页码:2165 / 2173
页数:9
相关论文
共 38 条